Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MRNA

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Kiplinger

Is Moderna Stock Underperforming the Nasdaq?

While Moderna has underperformed the broader Nasdaq index in 2024, analysts are reasonably bullish about the stock's potential.

Barchart

Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?

Moderna has underperformed many of its peers and the broader market YTD, but Wall Street analysts are optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to release its fiscal second-quarter earnings next month, and analysts project a narrower loss.

Barchart

Is Moderna Stock Outperforming the S&P 500?

Moderna recently outperformed the S&P 500, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

Is This Biotech Stock's OpenAI Partnership a Game-Changer?

With AI making waves in biotech, could this biotech’s OpenAI partnership be the catalyst for new highs?

Barchart

Is Wall Street Bullish or Bearish on Moderna Stock?

Moderna has outperformed many of its peers and the broader market YTD, but Wall Street analysts are cautiously optimistic about the stock's prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

StockNews.com

Moderna (MRNA) Earnings Analysis: Buy or Watch for Gains?

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash burn reflect uncertainty around its near-term prospects. As MRNA is set to release its fourth-quarter 2023 results this Thursday, let’s find…

StockNews.com

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

StockNews.com

Moderna (MRNA) vs. Exelixis (EXEL) - Which Biotech Stock Is Worth Buying?

The biotech industry is poised for long-term growth, supported by the advancements in personalized medicine and integration with information technology. While leading biotech stocks Moderna (MRNA) and Exelixis (EXEL) should benefit from the industry tailwinds, let us predict which stock is worth buying.

StockNews.com

Moderna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?

The biotech industry is growing as a result of steady demand and tech advancements. Therefore, let’s assess the prospects of biotech stocks Acorda Therapeutics (ACOR) and Moderna (MRNA). Read on.

StockNews.com

Moderna (MRNA) and 2 More Biotech Stocks That Are Worth Watching

Growing demand for personalized medicines and rising adoption of machine learning tools are expected to boost the biotech industry. Therefore, it could be wise to watch fundamentally strong biotech stocks Moderna (MRNA), Amicus Therapeutics (FOLD), and Entrada Therapeutics (TRDA). Read more.

StockNews.com

Bearish Outlook? Try These Bear Call Spread Trades

A bear call spread is a type of vertical spread, meaning that two options within the same expiry month are being traded.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Moderna (MRNA) Stock Analysis: Is the Biotech Stock a Buy at This Time?

Biotech company Moderna (MRNA) recently published positive data from its latest flu vaccine trial, garnering investors’ attention. While the company focusing on expanding its product portfolio, is this the right time to invest in its stock? Keep reading.

Barchart

This Biotech Stock Offers Innovative Growth at a Massive Discount

Moderna stock continues to sag, even as new COVID variants emerge. However, investors may be underestimating the potential of the mRNA pipeline.

StockNews.com

Which of These 3 Biotech Stocks Are a Buy, Sell, or Hold?

Advanced medical technologies and the pivotal role of technology in drug development are poised to drive significant growth in the biotech industry. Against this backdrop, should you buy, sell or hold biotech stocks Moderna (MRNA), MacroGenics (MGNX), and Amicus Therapeutics (FOLD)? Let’s find out….

StockNews.com

Is Now the Time to Buy Into Moderna, Inc. (MRNA)?

Is now the time to invest in Moderna (MRNA) after the company revealed that its updated vaccines would be effective against two new COVID-19 subvariants? Let’s look at its financial metrics to gauge its prospects….

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Moderna (MRNA) vs. Amicus Therapeutics (FOLD): Which Biotech Stock Should You Add to Your Portfolio?

Healthcare is considered a reliable defensive sector. So, amid the current uncertain economic landscape, let's determine the more favorable investment option between two prominent pharmaceutical companies, Moderna (MRNA) and Amicus Therapeutics (FOLD). Keep reading.

Barchart

Is the Rally Getting Long in the Tooth? Try These Bear Call Spread Trades

Traders should have a bearish outlook on the stock and ideally look to enter when the stock has a high implied volatility rank.

Zenger

Moderna Stock Rises After FDA Application For Updated Vaccine

Moderna's potential beyond COVID-19 is underappreciated, says analyst Eliana Merle, who upgraded the stock to Buy

StockNews.com

Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Should You Be Investing In?

Amidst the biotech industry’s rapid growth and notable advancements, let’s analyze which of the two major players, Moderna (MRNA) and BioNTech (BNTX), is a more favorable investment choice in the current uncertain economic climate. Keep reading to find out.

StockNews.com

Buy, Hold or Sell? Gilead Sciences Inc. (GILD) and Moderna Inc. (MRNA)

Rapid breakthroughs and surging demand position the biotech sector for significant expansion in the near term. Therefore, quality biotech stock Gilead Sciences (GILD) could be worth buying. However, I think it will be best to wait for a better entry point in Moderna (MRNA). Read on.

Kiplinger

Moderna Stock Pops on Surprise Earnings Beat

An unexpected profit and promising news on a deal with the EU boosted Moderna stock.

StockNews.com

Investing Champion Leif Soreide Notes Biotech Stocks May Be Countercyclical

Biotech stocks can often be countercyclical, according to some market experts. We explore some biotech opportunities in this article.

1 2 3 4 5

People

Kritika SarmahHer

727 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.